Toshiyuki Kozuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshiyuki Kozuki has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
- Koichi Azuma
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan
37 shared publications - Makoto Nishio
Department of Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan
37 shared publications - Miyako Satouchi
Department of Thoracic Oncology Hyogo Cancer Center Akashi Japan
37 shared publications - Daichi Fujimoto
Internal Medicine III Wakayama Medical University Wakayama Japan
36 shared publications - Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
36 shared publications - Shunichi Sugawara
Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
36 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Elsevier in SSRN Electronic Journal
A phase II multicenter investigator-initiated study of the PAI-1 inhibitor TM5614 in combination with concurrent chemoradiotherapy followed by durvalumab consolidation for patients with unresectable locally advanced non-small cell lung cancer
Background: Concurrent chemoradiotherapy followed by durvalumab consolidation is the standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). However, locoregional recurrence, distant metastasis, and treatment-related pneumonitis remain significant clinical challenges. Plasminogen activator inhibitor-1 (PAI-1) contributes to tumor progression, radioresistance, immune evasion, and fibrosis. Preclinical studies have shown that PAI-1 inhibition enhances the antitumor effects of radiotherapy and immunotherapy while mitigating radiation-induced pulmonary fibrosis. TM5614 is an orally available small-molecule PAI-1 inhibitor.Methods: This multicenter, open-label, single-arm, phase II investigator-initiated trial evaluates TM5614 in combination with concurrent chemoradiotherapy followed by durvalumab consolidation in patients with unresectable stage III NSCLC. Eligible patients are 18 to 80 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, measurable disease according to RECIST version 1.1, and no activating EGFR mutations or ALK rearrangements. Participants receive weekly carboplatin (area under the curve [AUC] 2), paclitaxel (40 mg/m²), thoracic radiotherapy (60 Gy in 30 fractions), and oral TM5614 (180 mg/day). Patients without disease progression subsequently receive durvalumab (1500 mg every 4 weeks for up to 1 year) with continued TM5614 administration. The primary endpoint is the 1-year progression-free survival rate. Secondary endpoints include objective response rate, disease control rate, progression-free survival, overall survival, and safety. A total of 27 patients will be enrolled.Conclusion: To our knowledge, this is the first prospective trial to evaluate PAI-1 inhibition during definitive chemoradiotherapy followed by durvalumab consolidation in patients with locally advanced NSCLC. TM5614 may improve antitumor efficacy and pulmonary safety by simultaneously targeting radioresistance, immunosuppression, and fibrosis.
- 5 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA phase II multicenter investigator-initiated study of the PAI-1 inhibitor TM5614 in combination with concurrent chemoradiotherapy followed by durvalumab consolidation for patients with unresectable locally advanced non-small cell lung cancer
Background: Concurrent chemoradiotherapy followed by durvalumab consolidation is the standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). However, locoregional recurrence, distant metastasis, and treatment-related pneumonitis remain significant clinical challenges. Plasminogen activator inhibitor-1 (PAI-1) contributes to tumor progression, radioresistance, immune evasion, and fibrosis. Preclinical studies have shown that PAI-1 inhibition enhances the antitumor effects of radiotherapy and immunotherapy while mitigating radiation-induced pulmonary fibrosis. TM5614 is an orally available small-molecule PAI-1 inhibitor.Methods: This multicenter, open-label, single-arm, phase II investigator-initiated trial evaluates TM5614 in combination with concurrent chemoradiotherapy followed by durvalumab consolidation in patients with unresectable stage III NSCLC. Eligible patients are 18 to 80 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, measurable disease according to RECIST version 1.1, and no activating EGFR mutations or ALK rearrangements. Participants receive weekly carboplatin (area under the curve [AUC] 2), paclitaxel (40 mg/m²), thoracic radiotherapy (60 Gy in 30 fractions), and oral TM5614 (180 mg/day). Patients without disease progression subsequently receive durvalumab (1500 mg every 4 weeks for up to 1 year) with continued TM5614 administration. The primary endpoint is the 1-year progression-free survival rate. Secondary endpoints include objective response rate, disease control rate, progression-free survival, overall survival, and safety. A total of 27 patients will be enrolled.Conclusion: To our knowledge, this is the first prospective trial to evaluate PAI-1 inhibition during definitive chemoradiotherapy followed by durvalumab consolidation in patients with locally advanced NSCLC. TM5614 may improve antitumor efficacy and pulmonary safety by simultaneously targeting radioresistance, immunosuppression, and fibrosis.
- Open Access
- 26 September 2026
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 64
Successful clinical remission of severe asthma with small airway dysfunction and eosinophilic gastrointestinal disease using dupilumab after benralizumab failure
- 26 September 2026
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 64
Open AccessSuccessful clinical remission of severe asthma with small airway dysfunction and eosinophilic gastrointestinal disease using dupilumab after benralizumab failure
- Open Access
- 12 May 2026
- Published by Elsevier in Lung Cancer
- Vol. 217, 109447
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer
- 12 May 2026
- Published by Elsevier in Lung Cancer
- Vol. 217, 109447
Open AccessFinal overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer
- Open Access
- 22 November 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (1) , 101332
Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study
- 22 November 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (1) , 101332
Open AccessIncidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Time to Onset of First Hepatotoxicity Event
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Time to Onset of First Hepatotoxicity Event
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Preclinical efficacy study with xenograft models derived from patients with SCLC
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Preclinical efficacy study with xenograft models derived from patients with SCLC
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Representativeness of Study Participants
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Representativeness of Study Participants
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Mean (± SD) preliminary ABBV-011 ADC concentration-time profiles following IV infusion of ABBV-011 (0.3 to 2.0 mg/kg) in cycle 1
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Mean (± SD) preliminary ABBV-011 ADC concentration-time profiles following IV infusion of ABBV-011 (0.3 to 2.0 mg/kg) in cycle 1
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Overview of Treatment Response by Line of Treatment and Platinum Sensitivity
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Overview of Treatment Response by Line of Treatment and Platinum Sensitivity